Zymeworks Inc. (ZYME) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 20 analysts75.8% Below Target
ZYME trades 75.8% below Wall Street's consensus target of $40.67.
Current Price$23.14
Average Target$40.67
Target
Current
Low$28.00
Median$46.00
High$48.00
Analyst Target Range
Forward P/E16.9x
(Fair)
PEG Ratio—
Implied Growth+199.5%
(High Growth)
Analyst Spread49.2%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes ZYME achieves its forward estimates and maintains a stable P/E multiple of 16.9x. This scenario reflects the blended consensus of 20 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
ZYME Price Target Analysis
Updated June 20, 2026As of June 20, 2026, Zymeworks Inc. (ZYME) has a Wall Street consensus price target of $40.67, based on estimates from 20 covering analysts. With the stock currently trading at $23.14, this represents a potential upside of +75.8%. The company has a market capitalization of $1.70B.
Analyst price targets range from a low of $28.00 to a high of $48.00, representing a 49% spread in expectations. The median target of $46.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ZYME trades at a trailing P/E of -21.4x and forward P/E of 16.9x. Analysts expect EPS to grow +199.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+806.1%
Industry Consensus
Avg Forward P/E
9.5x
(Value)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $7.3B | $35.34 | $45.00 | +27.3% | Buy | — | 23 |
 RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
 MRUSMerus N.V. | $6.8B | $90.00 | $88.69 | -1.5% | Hold | — | 22 |
 AGIOAgios Pharmaceuticals, Inc. | $2.0B | $34.16 | $43.33 | +26.8% | Buy | — | 29 |
 TPSTTempest Therapeutics, Inc. | $5M | $1.23 | — | — | — | — | — |
 ABBVAbbVie Inc. | $383.2B | $216.63 | $256.92 | +18.6% | Buy | 15.2x | 41 |
 ARVNArvinas, Inc. | $495M | $7.67 | $14.75 | +92.3% | Buy | — | 26 |
 BCABBioAtla, Inc. | $5M | $3.65 | $250.00 | +6739.9% | Buy | — | 9 |
 AGENAgenus Inc. | $125M | $3.00 | $7.33 | +144.3% | Buy | 3.8x | 11 |
 XNCRXencor, Inc. | $927M | $12.64 | $35.30 | +179.3% | Buy | — | 27 |
ZYME — Frequently Asked Questions
Quick answers to the most common questions about buying ZYME stock.
What is the ZYME stock price target for 2026?
The consensus Wall Street price target for ZYME is $40.67, representing 75.8% upside from the current price of $23.14. With 20 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is ZYME a buy, sell, or hold?
ZYME has a consensus rating of "Buy" based on 20 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $40.67 implies 75.8% upside from current levels.
Is ZYME stock overvalued or undervalued?
With a forward P/E of 16.9301x, ZYME trades at a relatively low valuation. The consensus target of $40.67 implies 75.8% appreciation, suggesting meaningful undervaluation.
How high can ZYME stock go?
The most bullish Wall Street analyst has a price target of $48 for ZYME, while the most conservative target is $28. The consensus of $40.67 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover ZYME stock?
ZYME is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ZYME stock forecast?
The 12-month ZYME stock forecast based on 20 Wall Street analysts shows a consensus price target of $40.67, with estimates ranging from $28 (bear case) to $48 (bull case). The median consensus rating is "Buy".
What is ZYME's forward P/E ratio?
ZYME trades at a forward P/E ratio of 16.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy ZYME stock?
Wall Street analysts are very optimistic on ZYME, with a "Buy" consensus rating and $40.67 price target (75.8% upside). 18 of 20 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ZYME price targets vary so much?
ZYME analyst price targets range from $28 to $48, a 49% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $40.67 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare